Ligand to Participate in Three Upcoming Investor Conferences
Ligand to Report First Quarter Results on May 7th
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL® (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Captisol® Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia
Ligand to Present at the 26th Annual Roth Conference on March 11
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
Ligand to Receive $1 Million Kyprolis® Commercial Milestone Payment from Onyx Pharmaceuticals
Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia
Ligand to Report Fourth Quarter Results on February 11th
